| pubmed-article:8085975 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8085975 | lifeskim:mentions | umls-concept:C0007082 | lld:lifeskim |
| pubmed-article:8085975 | lifeskim:mentions | umls-concept:C0007102 | lld:lifeskim |
| pubmed-article:8085975 | lifeskim:mentions | umls-concept:C0494165 | lld:lifeskim |
| pubmed-article:8085975 | lifeskim:mentions | umls-concept:C0010412 | lld:lifeskim |
| pubmed-article:8085975 | lifeskim:mentions | umls-concept:C0038952 | lld:lifeskim |
| pubmed-article:8085975 | lifeskim:mentions | umls-concept:C0681842 | lld:lifeskim |
| pubmed-article:8085975 | lifeskim:mentions | umls-concept:C0301630 | lld:lifeskim |
| pubmed-article:8085975 | pubmed:issue | 9 | lld:pubmed |
| pubmed-article:8085975 | pubmed:dateCreated | 1994-10-11 | lld:pubmed |
| pubmed-article:8085975 | pubmed:abstractText | Serum carcinoembryonic antigen (CEA) levels in 33 Australian patients with hepatic metastases from colorectal cancer were measured before and after treatment with hepatic cryotherapy and intra-arterial chemotherapy. Pre-operative and monthly postoperative CEA measurements were made and the lowest postoperative reading was recorded as a percentage fall from the pre-operative level. There was a highly significant association between the maximum percentage fall in CEA and survival. A 50% increase in the maximum percentage fall in CEA level was associated with one-tenth the risk of death (95% CI RR 0.03 to 0.32, Cox regression). It is estimated that an increase in the maximum percentage fall in CEA of 50% from 25 to 75% was associated with an increase in the median survival from 240 days to over 2 years. | lld:pubmed |
| pubmed-article:8085975 | pubmed:language | eng | lld:pubmed |
| pubmed-article:8085975 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8085975 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:8085975 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8085975 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8085975 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8085975 | pubmed:month | Sep | lld:pubmed |
| pubmed-article:8085975 | pubmed:issn | 0004-8682 | lld:pubmed |
| pubmed-article:8085975 | pubmed:author | pubmed-author:KingJJ | lld:pubmed |
| pubmed-article:8085975 | pubmed:author | pubmed-author:MorrisD LDL | lld:pubmed |
| pubmed-article:8085975 | pubmed:author | pubmed-author:RossW BWB | lld:pubmed |
| pubmed-article:8085975 | pubmed:author | pubmed-author:ClinganP RPR | lld:pubmed |
| pubmed-article:8085975 | pubmed:author | pubmed-author:CaplehornJ... | lld:pubmed |
| pubmed-article:8085975 | pubmed:author | pubmed-author:PreketesA PAP | lld:pubmed |
| pubmed-article:8085975 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8085975 | pubmed:volume | 64 | lld:pubmed |
| pubmed-article:8085975 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8085975 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:8085975 | pubmed:pagination | 612-4 | lld:pubmed |
| pubmed-article:8085975 | pubmed:dateRevised | 2004-11-17 | lld:pubmed |
| pubmed-article:8085975 | pubmed:meshHeading | pubmed-meshheading:8085975-... | lld:pubmed |
| pubmed-article:8085975 | pubmed:meshHeading | pubmed-meshheading:8085975-... | lld:pubmed |
| pubmed-article:8085975 | pubmed:meshHeading | pubmed-meshheading:8085975-... | lld:pubmed |
| pubmed-article:8085975 | pubmed:meshHeading | pubmed-meshheading:8085975-... | lld:pubmed |
| pubmed-article:8085975 | pubmed:meshHeading | pubmed-meshheading:8085975-... | lld:pubmed |
| pubmed-article:8085975 | pubmed:meshHeading | pubmed-meshheading:8085975-... | lld:pubmed |
| pubmed-article:8085975 | pubmed:meshHeading | pubmed-meshheading:8085975-... | lld:pubmed |
| pubmed-article:8085975 | pubmed:meshHeading | pubmed-meshheading:8085975-... | lld:pubmed |
| pubmed-article:8085975 | pubmed:meshHeading | pubmed-meshheading:8085975-... | lld:pubmed |
| pubmed-article:8085975 | pubmed:meshHeading | pubmed-meshheading:8085975-... | lld:pubmed |
| pubmed-article:8085975 | pubmed:meshHeading | pubmed-meshheading:8085975-... | lld:pubmed |
| pubmed-article:8085975 | pubmed:meshHeading | pubmed-meshheading:8085975-... | lld:pubmed |
| pubmed-article:8085975 | pubmed:meshHeading | pubmed-meshheading:8085975-... | lld:pubmed |
| pubmed-article:8085975 | pubmed:meshHeading | pubmed-meshheading:8085975-... | lld:pubmed |
| pubmed-article:8085975 | pubmed:year | 1994 | lld:pubmed |
| pubmed-article:8085975 | pubmed:articleTitle | CEA reduction after cryotherapy for liver metastases from colon cancer predicts survival. | lld:pubmed |
| pubmed-article:8085975 | pubmed:affiliation | University of New South Wales Department of Surgery, St George Hospital, Kogarah, Sydney, Australia. | lld:pubmed |
| pubmed-article:8085975 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8085975 | lld:pubmed |
